IBRX

A month has gone by since the last earnings report for ImmunityBio (IBRX). Shares have added about 9.7% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is ImmunityBio due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for ImmunityBio, Inc. before we dive into how investors and analysts have reacted as of late. ImmunityBio reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period’s loss of 10 cents. Total revenues surged nearly 94% year over year to $51.2 million, beating the Zacks Consensus Estimate of $48.5 million. The top-line performance reflected continued adoption of the company’s sole marketed drug, Anktiva, among U.S. urologists and strong market access. Net product revenues, which accounted for nearly all quarterly revenues, reached a record $50.7 million, rising 92% year over year and 15% sequentially. The product performance marked ImmunityBio’s eighth consecutive quarter of sequential net product revenue growth since Anktiva’s commercial launch. Other revenues totaled $0.6 million. Total operating costs and expenses increased about 16% year over year to around $113 million. Research and development expenses grew 10% to nearly $61 million. The increase reflected higher personnel-related costs, clinical trial expenses and external manufacturing and distribution costs. Selling, general and administrative expenses climbed 22% year over year to about $52 million. The increase stemmed mainly from higher professional services, personnel-related and commercial expenses. In the past month, investors have witnessed a upward trend in estimates review. The consensus estimate has shifted 6.25% due to these changes. At this time, ImmunityBio has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock has a score of F on the value side, putting it in the fifth quintile for value investors. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, ImmunityBio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. ImmunityBio belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Repligen (RGEN), has gained 9.1% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Repligen reported revenues of $204.13 million in the last reported quarter, representing a year-over-year change of +11.9%. EPS of $0.54 for the same period compares with $0.37 a year ago. For the current quarter, Repligen is expected to post earnings of $0.46 per share, indicating no change from the year-ago quarter. The Zacks Consensus Estimate has changed -0.1% over the last 30 days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for Repligen. Also, the stock has a VGM Score of F. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ImmunityBio, Inc. (IBRX) : Free Stock Analysis Report Repligen Corporation (RGEN) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

ImmunityBio IBRX reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period’s loss of 10 cents. Total revenues surged nearly 94% year over year to $51.2 million, beating the Zacks Consensus Estimate of $48.5 million. Year to date, shares of ImmunityBio have skyrocketed 251% compared with the industry’s nearly 3% growth. Image Source: Zacks Investment Research The top-line performance reflected continued adoption of the company’s sole marketed drug, Anktiva, among U.S. urologists and strong market access. Net product revenues, which accounted for nearly all quarterly revenues, reached a record $50.7 million, rising 92% year over year and 15% sequentially. The product performance marked ImmunityBio’s eighth consecutive quarter of sequential net product revenue growth since Anktiva’s commercial launch. Other revenues totaled $0.6 million. Total operating costs and expenses increased about 16% year over year to around $113 million. Research and development expenses grew 10% to nearly $61 million. The increase reflected higher personnel-related costs, clinical trial expenses and external manufacturing and distribution costs. Selling, general and administrative expenses climbed 22% year over year to about $52 million. The increase stemmed mainly from higher professional services, personnel-related and commercial expenses. Last month, the United Arab Emirates granted broad marketing authorization for Anktiva across BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for carcinoma in situ (CIS) and papillary disease, as well as metastatic non-small cell lung cancer (NSCLC). The authorization expanded Anktiva’s regulatory footprint. An FDA filing is under review, seeking label expansion for Anktiva plus BCG in patients with BCG-unresponsive NMIBC with papillary disease without CIS. A final decision is expected by Jan. 6, 2027. ImmunityBio also intends to submit another regulatory filing later this year, seeking to expand Anktiva’s label in patients with BCG-naïve NMIBC with CIS, with or without papillary disease. Multiple regulatory, clinical and data milestones are expected over the next 12 months. Iovance currently carries a Zacks Rank #3 (Hold). ImmunityBio, Inc. price | ImmunityBio, Inc. Quote Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, earnings per share (EPS) estimates for Harmony Biosciences have risen from $3.20 to $3.33 for 2026. Over the same period, EPS estimates have increased from $3.64 to $3.87 for 2027. HRMY shares have about 4% year to date. Harmony Biosciences missed earnings in three of the trailing four quarters while meeting on one occasion, delivering an average negative surprise of 13.97%. Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen from $4.81 to $5.31. LQDA shares have skyrocketed 156% so far this year. Liquidia’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, with the average surprise being 54.40%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ImmunityBio, Inc. (IBRX) : Free Stock Analysis Report Liquidia Corporation (LQDA) : Free Stock Analysis Report Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

CEO Richard Adcock apparently said that Anktiva sales remain “incredibly strong” and continue at the same pace. Koyfin expects quarterly revenue of $49.7 million, up 12% sequentially, with GAAP loss per share narrowing to $0.09. Retail traders are looking for a bigger beat, with estimates ranging from about $51 million to as high as $60 million-$63 million. Shares of ImmunityBio, Inc. (IBRX) are extending a five-session losing streak, but retail traders are looking to next week’s earnings for signs that “incredibly strong” Anktiva sales can reverse the slide. IBRX stock slipped 0.3% on Tuesday, with shares on track to log their fourth straight week in the red. See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox The focus is on commercial momentum for Anktiva, ImmunityBio’s flagship immunotherapy, after CEO Richard Adcock apparently struck an upbeat tone at a BTIG virtual conference ahead of the company’s expected quarterly report next week.  According to a trader following Adcock’s BTIG appearance, the CEO said sales were continuing “at the same pace” and later described them as “incredibly strong.” Koyfin estimates call for quarterly revenue of $49.7 million, up 12% from the prior quarter. Profitability is also expected to improve, with GAAP loss per share narrowing to $0.09 from $0.62, while adjusted loss per share is expected to remain at $0.08. Retail expectations are running hotter than consensus, with traders dissecting comments from the company, treatment volumes and international sales ahead of the second-quarter (Q2) print. However, retail sentiment on Stocktwits for IBRX was ‘bearish’ amid an 18% rise in 24-hour message volumes. One investor expects about $51 million in quarterly revenue, while another cited a Street estimate around $49 million and a “whisper” range of $52 million to $54 million. Others have floated even more aggressive numbers, including $60 million to $63 million in Q2 sales. One trader said repeat dosing of existing patients could produce a much stronger quarter than expected, saying the “potential for a huge quarter does exist” and that “EVERYONE has Underestimated the Potential.” Another trader said: “Earnings beat will stop the bleeding.” Retail investors are also watching for partnership or buyout developments. Some have speculated that a larger pharma company could help ImmunityBio accelerate global distribution, while others continue to view the company as a potential acquisition candidate if Anktiva sales keep expanding. Beyond the quarter, ImmunityBio is building a broader strategy around Anktiva and its natural killer, or NK, cell platform. Founder Patrick Soon-Shiong has outlined plans for a global “World Bank of NK Cells,” to create a scalable supply of cryopreserved, off-the-shelf NK cells that could be distributed to patients and deployed alongside Anktiva. The company is also developing automated manufacturing through its Nant Leonardo robotic platform. Soon-Shiong said in June that the NK-cell bank would ultimately be made available globally. Anktiva itself has also been expanding beyond the U.S., with ImmunityBio pursuing commercial and regulatory opportunities across Europe, Saudi Arabia and other markets. ImmunityBio also has a regulatory catalyst beyond the immediate earnings print. In May, the Food and Drug Administration accepted the company’s application seeking to expand Anktiva plus BCG into a broader group of patients with BCG-unresponsive non-muscle invasive bladder cancer, reversing an earlier refusal to review a similar filing. The agency set Jan. 6, 2027, as the target date for its decision. ImmunityBio has said its Quilt-3.032 study showed 58% of high-risk papillary bladder cancer patients remained disease-free at 12 months, while more than 80% avoided bladder-removal surgery through three years of follow-up. IBRX stock has jumped 163% over the past year. For updates and corrections, email newsroom[at]stocktwits[dot]com. Read Next: RKLB Stock Eyes Worst Month Ever, But Cathie Wood Keeps Buying — ARK Adds Rocket Lab, Cuts Exposure To $8B Takeover Target Deepti Sri has no position in any of the stocks mentioned in this article. StockTwits' news team content is for informational purposes only and is not intended as investment advice. For more, see our editorial policy. This article was originally published on StockTwits. Related: T, VZ, TMUS Stocks Are Sliding Today — Is There A SpaceX Connection? Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In Fed Keeps Rates Steady As Kevin Warsh Rules Out Softer Inflation Target — Says Will Not Hesitate To Fight Inflation

Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth. Click here to see the full list of 176 stocks from our Fast Growing US Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: ImmunityBio, Inc. is a biotechnology company dedicated to developing and commercializing advanced immunotherapies aimed at enhancing the immune system's response to cancer and infectious diseases, with a market cap of approximately $7.25 billion. Operations: The company generates revenue of $140.98 million from its segment focused on developing next-generation therapies. Insider Ownership: 28.2% Earnings Growth Forecast: 64.1% p.a. ImmunityBio, a growth-focused company with significant insider ownership, is advancing its ANKTIVA treatment for BCG-unresponsive non-muscle invasive bladder cancer. Recent FDA acceptance of its supplemental Biologics License Application could expand ANKTIVA's indications. Despite expected revenue growth of 47.8% annually, ImmunityBio faces financial challenges with less than a year of cash runway and recent shareholder dilution. Analysts agree on potential stock price appreciation, though the company currently trades significantly below estimated fair value. Unlock comprehensive insights into our analysis of ImmunityBio stock in this growth report. Upon reviewing our latest valuation report, ImmunityBio's share price might be too pessimistic. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Li Auto Inc. operates in the energy vehicle market in the People’s Republic of China with a market cap of approximately $14.48 billion. Operations: Li Auto generates revenue primarily from its auto manufacturing segment, totaling CN¥109.37 billion. Insider Ownership: 33% Earnings Growth Forecast: 61.6% p.a. Li Auto, characterized by high insider ownership, is navigating growth amid challenges. The company forecasts a 13% annual revenue increase, outpacing the US market. However, recent earnings revealed a net loss of CNY 2.29 billion for Q1 2026 despite vehicle deliveries reaching over 1.7 million year-to-date. Li Auto's strategic moves include a US$1 billion share buyback and launching new models like the Li L9 to bolster its position in the competitive electric vehicle sector. Take a closer look at Li Auto's potential here in our earnings growth report. Our expertly prepared valuation report Li Auto implies its share price may be too high. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Ethos Technologies Inc. operates as a third-party administrator for insurance policies in the United States and has a market cap of approximately $1.06 billion. Operations: The company generates revenue primarily from its insurance broker services, amounting to $485.82 million. Insider Ownership: 22% Earnings Growth Forecast: 94.5% p.a. Ethos Technologies, with significant insider ownership, is expanding its digital life insurance offerings through strategic partnerships and technological advancements. Recent collaborations with Liberty Mutual and Banner Life Insurance enhance Ethos' reach and product portfolio. Despite a Q1 2026 net loss of US$166.39 million, revenue surged to US$193.1 million from the previous year. The launch of a ChatGPT app signifies their innovative approach to consumer engagement in the evolving insurance landscape, although insider selling has been noted recently. Navigate through the intricacies of Ethos Technologies with our comprehensive analyst estimates report here. Upon reviewing our latest valuation report, Ethos Technologies' share price might be too optimistic. Click this link to deep-dive into the 176 companies within our Fast Growing US Companies With High Insider Ownership screener. Curious About Other Options? This technology could replace computers: discover the 30 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include IBRX LI and LIFE. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

ImmunityBio IBRX enters the post-earnings stretch with the stock at $7.72 (as of May 28, 2026) and a six to12 month price target of $8.25. After a 289.9% year-to-date surge, the setup is less about “what’s next” and more about what has already been priced in. The base case is an in-line performance profile tied to Anktiva’s commercial trajectory, with near-term upside requiring continued proof that demand is still accelerating after the run. IBRX has already delivered a sharp rerating, and the valuation reflects it. The shares are trading at 23.41x forward twelve-month sales versus 1.96x for the Zacks sub-industry, 2.12x for the Zacks sector and 5.25x for the S&P 500. That gap raises the bar for execution, especially for a company whose revenue base is still concentrated in a single marketed product. Against that backdrop, the $8.25 six to 12 month price target implies a more measured path from here. For investors, the practical question is whether the next few quarters extend the current adoption trend enough to justify what the market is already discounting after the stock’s outsized move. First-quarter 2026 results landed as a modest earnings miss with a revenue beat. ImmunityBio posted an adjusted loss of 9 cents per share versus the consensus loss of 8 cents, while revenue came in at $44.2 million versus $41.1 million. The adjusted figure excluded a large one-time fair-value change tied to warrant and derivative liabilities as well as the related-party convertible note. Including that line item, loss per share was 62 cents, compared with 15 cents a year ago. In other words, the quarter was not clean, but the core takeaway stayed centered on whether Anktiva’s commercial ramp remains intact. The quarter reinforced a demand narrative that is increasingly about breadth, not just initial uptake. Management pointed to strong demand from new prescribers and broader use across eligible patients, including in the maintenance setting. That matters because repeat ordering is the clearest sign that early trial use is translating into routine practice. Management framed repeat ordering as a driver of continued momentum, supporting quarter-over-quarter growth since launch. ImmunityBio, Inc. price | ImmunityBio, Inc. Quote The commercial build is showing up in operating expenses. Research and development expense rose to $68 million from $48.2 million a year earlier, driven by higher clinical study costs, headcount-related expenses, consulting fees and external manufacturing costs. Selling, general and administrative expense increased to $45.8 million from $32.7 million, reflecting higher professional services and headcount-related costs, plus incremental commercial spending and other items tied to scaling operations. The investment cadence underscores an “earnings later” posture that puts even more weight on sustaining the top-line trajectory. International expansion broadens the long-term opportunity, but the near-term math can be slow. Europe still requires country-by-country reimbursement, with the Big 5 prioritized and Germany expected to commercialize first in 2026. That implies a ramp that may extend into 2027, keeping near-term results disproportionately dependent on the U.S. trajectory. The company has made progress in securing authorizations across multiple jurisdictions, and commercial availability in Saudi Arabia was achieved quickly after announcing Middle East partnerships. Still, stepwise timing and access decisions can vary by country, and reimbursement friction can delay demand conversion even after regulatory wins. ImmunityBio ended March 2026 with nearly $381 million in cash, cash equivalents and marketable securities, alongside approximately $678 million in total debt (long-term only). The balance sheet also includes sizable fair-value liabilities, including a related-party convertible note valued at $678 million and a $404 million revenue interest liability. Management provides no margin or EPS guidance, which increases the importance of execution and adoption timing. Regulatory and compliance items can also be a distraction: the company received FDA promotional correspondence and implemented enhanced review protocols. A workable “hold vs. add” framework starts with what would validate the bullish path. First, investors should look for continued U.S. net product revenues acceleration beyond the 168% year over year and 15% sequential growth rate posted in the first quarter. Second, steady progress converting ex-U.S. authorizations into real demand would help reduce the company’s dependence on a single geography, even if the ramp remains gradual. Third, clean regulatory progress in bladder cancer matters, with the FDA reviewing a filing for Anktiva plus BCG in BCG-unresponsive papillary-only disease and a final decision expected by Jan. 6, 2027, while a BCG-naïve CIS program is positioned for an sBLA submission in 2026. The bear case is easier to define because it ties directly to timing risk. Slower launches or reimbursement delays in Europe could extend U.S. dependence longer than investors expect. Adoption disappointments would be harder to absorb given the elevated sales multiple. And regulatory or legal distractions, including promotional correspondence, could divert attention during a scaling phase. In the near term, a Zacks Rank #3 (Hold) aligns with a wait-for-confirmation posture. Industry peers such as Agenus AGEN and Iovance Biotherapeutics IOVA also carry a Zacks Rank #3, reinforcing that this pocket of biotech remains selective and execution-driven rather than broadly risk-on. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report ImmunityBio, Inc. (IBRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Shareholders of ImmunityBio, Inc. (NASDAQ:IBRX) will be pleased this week, given that the stock price is up 15% to US$8.51 following its latest quarterly results. It was a pretty bad result overall; while revenues were in line with expectations at US$44m, statutory losses exploded to US$0.62 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Taking into account the latest results, the current consensus from ImmunityBio's four analysts is for revenues of US$229.8m in 2026. This would reflect a substantial 63% increase on its revenue over the past 12 months. Losses are expected to increase slightly, to US$0.83 per share. Before this earnings announcement, the analysts had been modelling revenues of US$218.7m and losses of US$0.26 per share in 2026. So it's pretty clear the analysts have mixed opinions on ImmunityBio even after this update; although they upped their revenue numbers, it came at the cost of a massive increase in per-share losses. See our latest analysis for ImmunityBio There was no major change to the consensus price target of US$15.25, with growing revenues seemingly enough to offset the concern of growing losses. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on ImmunityBio, with the most bullish analyst valuing it at US$22.00 and the most bearish at US$12.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the ImmunityBio's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of ImmunityBio'shistorical trends, as the 92% annualised revenue growth to the end of 2026 is roughly in line with the 90% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 22% per year. So although ImmunityBio is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry. The most important thing to take away is that the analysts increased their loss per share estimates for next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for ImmunityBio going out to 2028, and you can see them free on our platform here.. You should always think about risks though. Case in point, we've spotted 4 warning signs for ImmunityBio you should be aware of, and 3 of them are a bit unpleasant. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Q1 2026 Revenue Growth with Continued Strong Sales Momentum: $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 and up 15% from Q4 2025 ANKTIVA® Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025 ANKTIVA Regulatory Update: ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries, including first approval in Asia by the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region of the People’s Republic of China. Commercial availability achieved within two months of announcing MENA partnership with Biopharma and Cigalah Healthcare. Cash Position: $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026, up from $242.8 million as of December 31, 2025. Pivotal BCG-Naïve CIS trial (QUILT-2.005): Fully enrolled, with the Independent Data Monitoring Committee (IDMC) confirming no additional enrollment is required. A supplemental BLA (sBLA) submission is on track for 2026 BCG-Unresponsive NMIBC with Papillary-Only Disease Category 2A NCCN® Recommendation: NCCN Clinical Practice Guidelines in Oncology have been updated to include ANKTIVA plus BCG for patients with BCG-unresponsive NMIBC with papillary-only disease in addition to CIS, with or without papillary tumors. Both recommendations are Category 2A, representing uniform consensus. CULVER CITY, Calif., May 07, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company, announced financial and operational highlights for the fiscal quarter ended March 31, 2026. The Company reported net product revenue of approximately $44.2 million during the three months ended March 31, 2026, with net product revenue growth in every quarter since ANKTIVA’s commercial launch, including a 168% increase over Q1 2025. This builds on full-year 2025 net product revenue of $113.0 million, a 700% increase over full-year 2024. Q1 2026 net product revenue also represents a 15% sequential increase over the $38.3 million earned during Q4 2025, and the revenue growth expansion of 700% full year growth year-over-year in 2025 continues. The Company ended the quarter with $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026. "We continue to see strong demand for ANKTIVA from both new prescribers and physicians expanding use across multiple eligible patients, including in the maintenance setting," said Richard Adcock, President and CEO of ImmunityBio. "We have also made meaningful progress expanding market access beyond the U.S., with ANKTIVA now commercially available in Saudi Arabia and additional markets anticipated this year. We are entering Q2 with a strong cash position, growing revenues, and a more experienced commercial organization positioned to support continued growth." "We’re encouraged by the steady progress of our clinical programs and regulatory submissions across NMIBC and non-small cell lung cancer (NSCLC)," said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. "The full enrollment of our pivotal BCG-naïve NMIBC trial, with independent confirmation that no additional patients are required, supports our planned sBLA submission in 2026. In parallel, recent NCCN guideline updates now include ANKTIVA plus BCG for patients with BCG-unresponsive papillary-only disease, reinforcing the growing clinical evidence supporting our approach across a broader spectrum of bladder cancer patients. We are also advancing our NSCLC program in a randomized trial in patients who have progressed following prior checkpoint inhibitor therapy, an area of significant unmet need, alongside continued development of our cell therapy platforms, including CD19-targeted therapies in non-Hodgkin lymphoma and Waldenström’s macroglobulinemia, and PD-L1 t-haNK in glioblastoma." Quarterly Financial Highlights Cash and Marketable Securities Position As of March 31, 2026, the Company had consolidated cash, cash equivalents, and marketable securities of $380.9 million. First-Quarter 2026 Financial Summary Product Revenue, Net Product revenue, net increased $27.7 million during the three months ended March 31, 2026, as compared to the three months ended March 31, 2025, due to increased net trade sales of ANKTIVA as a result of ongoing commercial activities. Research and Development Expense Research and development (R&D) expense increased $19.8 million to $68.0 million during the three months ended March 31, 2026, as compared to $48.2 million during the three months ended March 31, 2025, mainly due to increased clinical trials costs, headcount-related costs, consulting fees, and external manufacturing costs. Selling, General and Administrative Expense Selling, general and administrative (SG&A) expense increased $13.1 million to $45.8 million during the three months ended March 31, 2026, as compared to $32.7 million during the three months ended March 31, 2025, mainly due to increased professional services expenses, headcount-related costs, commercial-related expenses, other expense, and equipment expense. Other Expense, Net Other expense, net increased $497.5 million to $563.0 million during the three months ended March 31, 2026, as compared to $65.5 million during the three months ended March 31, 2025, primarily due to non-cash changes in the fair value of liabilities mainly driven by the significant increase in our common stock price. These fair value changes impacted our warrant and derivative liabilities, and a related-party convertible note. We also recorded a one-time write off of a convertible note receivable. These changes were partially offset by an increase in interest and investment income and a decrease in interest expense due to lower interest rates. Net Loss Attributable to ImmunityBio Common Stockholders (Net Loss) Net loss attributable to ImmunityBio common stockholders was $632.8 million during the three months ended March 31, 2026, as compared to $129.6 million during the three months ended March 31, 2025. The increase in net loss was mainly driven by changes in fair value of warrant and derivative liabilities, and a related-party convertible note due to an increase in our common stock price during the quarter, and the write off of a convertible note receivable, and higher R&D and SG&A expenses described above, which were partially offset by higher product revenue. Adjusted Net Loss Attributable to ImmunityBio Common Stockholders (Adjusted Net Loss) Adjusted net loss attributable to ImmunityBio common stockholders increased $3.6 million to $86.2 million during the three months ended March 31, 2026, as compared to $82.7 million during the three months ended March 31, 2025. Adjusted net loss is a non-GAAP financial measure that excludes the impact of certain items, as shown in the non-GAAP reconciliation table below. ImmunityBio, Inc. Reconciliation of Net Loss Attributable to Common Stockholders (GAAP) to Adjusted Net Loss Attributable to Common Stockholders (Non-GAAP) Adjusted net loss attributable to common stockholders is a non-GAAP financial measure which excludes certain items that are included in net loss attributable to common stockholders, the most directly comparable GAAP financial measure. Items excluded are those which the Company believes affect the comparability of operating results and are typically excluded from published estimates by the investment community, including items whose timing and/or amount cannot be reasonably estimated or are non-recurring. Adjusted net loss attributable to common stockholders is presented because management believes it provides useful additional information to investors for analysis of the Company’s fundamental business on a recurring basis. In addition, management believes that adjusted net loss attributable to common stockholders is widely used by professional research analysts and others in the valuation, comparison, and investment recommendations of companies such as ImmunityBio. Adjusted net loss attributable to common stockholders should not be considered in isolation or as a substitute for net loss attributable to common stockholders or any other measure of a company’s financial performance or profitability presented in accordance with GAAP. A reconciliation of the differences between net loss attributable to common stockholders and adjusted net loss attributable to common stockholders is presented below. Because adjusted net loss attributable to common stockholders excludes some, but not all, items that affect net loss attributable to common stockholders and may vary among companies, our calculation of adjusted net loss attributable to common stockholders may not be comparable to similarly titled measures of other companies. About ImmunityBio ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield™ platform, which is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via our proprietary IL-15 superagonist, ANKTIVA® (nogapendekin alfa inbakicept). Our Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements in this press release include, without limitation, statements regarding future operating results and prospects, global commercialization activities and expansion efforts and anticipated timelines, sales momentum and growth, market data, market access initiatives and potential platform expansion, expectations regarding FDA engagement, submissions, responses and timelines, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding participation and enrollment and potential results from clinical trials, (ii) whether clinical trials will result in registrational pathways, (iii) whether clinical trial data will be accepted by regulatory agencies, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (vi) potential delays in product availability and regulatory approvals, (vii) ImmunityBio’s ability to retain and hire key personnel, (viii) ImmunityBio’s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (ix) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (x) ImmunityBio’s ability to successfully commercialize its approved product and product candidates, (xi) ImmunityBio’s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xii) ImmunityBio’s ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio’s business are described under the heading "Risk Factors" in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 23, 2026 and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov. ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507366251/en/ Contacts IMMUNITYBIO MEDIA CONTACTS: Investor Relations: Hemanth Ramaprakash, PhD, MBA +1 858-746-9289 [email protected] Media: Sarah Singleton +1 415-290-8045 [email protected]

ImmunityBio IBRX is expected to report first-quarter 2026 results later this month. In the last reported quarter, the company delivered an earnings surprise of 25.00%. The Zacks Consensus Estimate for first-quarter 2026 revenues is pegged at $41.10 million, while the same for the bottom line is pegged at a loss of 8 cents per share. Let’s see how things might have shaped up for IBRX in the soon-to-be-reported quarter. ImmunityBio heads into its earnings release with strong momentum, largely driven by the rapid commercial uptake of its sole marketed drug, Anktiva. The drug is currently approved in the United States in combination with BCG for the treatment of adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. The company’s top line primarily comprises product sales from Anktiva, with only a modest contribution from other revenue streams. Last month, the company released preliminary figures for total net product revenues of approximately $44.2 million for the first quarter, reflecting 168% year-over-year growth and a 15% sequential increase. This upside was mainly driven by continued post-launch adoption of Anktiva. ImmunityBio, Inc. price-eps-surprise | ImmunityBio, Inc. Quote Investors will likely be interested in updates regarding IBRX’s pipeline progress and Anktiva’s expansion strategy on the first-quarter earnings call. ImmunityBio is pursuing additional label expansion opportunities for Anktiva. It recently resubmitted a supplemental regulatory filing with the FDA seeking label expansion for the combination of Anktiva and BCG in BCG-unresponsive NMIBC with papillary disease. Within bladder cancer, IBRX is advancing a randomized study evaluating Anktiva plus BCG in BCG-naïve NMIBC patients — a significantly larger population than the currently approved setting. The company is targeting a potential regulatory filing later this year, with additional studies exploring the therapy across other disease settings that could further expand its addressable market. Beyond bladder cancer, ImmunityBio is exploring Anktiva, in combination with standard-of-care therapies and CAR-NK approaches, across several difficult-to-treat cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma, colorectal cancer and hepatocellular carcinoma. In January, the therapy received its first regulatory approval in the NSCLC indication in Saudi Arabia. The company intends to hold discussions with the FDA later this year, seeking label expansion for the drug in a similar indication. ImmunityBio has a mixed history of earnings surprises. The company’s earnings beat estimates in two of the trailing four quarters, were in line in one, and missed the same on the remaining occasion, delivering an average surprise of 7.5%. Year to date, shares of ImmunityBio have surged 259.1% against the industry’s 2.4% decline. Image Source: Zacks Investment Research Our proven model does not conclusively predict an earnings beat for IBRX this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Earnings ESP: ImmunityBio has an Earnings ESP of 0.00%. Zacks Rank: ImmunityBio currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here. Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle. ANI Pharmaceuticals ANIP has an Earnings ESP of +7.81% and carries a Zacks Rank #3 at present. Shares of ANIP have risen 1.8% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 22.21%. United Therapeutics UTHR has an Earnings ESP of +2.24% and a Zacks Rank #3 at present. Shares of UTHR have risen 17.1% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 4.29%. United Therapeutics is scheduled to report first-quarter results on May 6. ACADIA Pharmaceuticals ACAD has an Earnings ESP of +75.24% and a Zacks Rank #3 at present. Shares of ACAD have plunged 17.8% year to date. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 35.83%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report United Therapeutics Corporation (UTHR) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ImmunityBio, Inc. (IBRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

ImmunityBio’s IBRX shares rose 7%, following the release of better-than-expected preliminary product revenues for first-quarter 2026. IBRX’s top line primarily comprises product sales from Anktiva, an IL-15 receptor agonist, which is the company's lead product and commercial growth driver. The drug is approved in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. Anktiva has now secured approvals across five regulatory jurisdictions, covering around 34 countries. Year to date, shares of IBRX have rallied 277.7% compared with the industry’s 2.1% growth. Image Source: Zacks Investment Research ImmunityBio expects net product revenues to be approximately $44.2 million in the first quarter of 2026, suggesting 168% year-over-year growth and a 15% sequential increase, driven by steady post-launch adoption. The preliminary figure beat the Zacks Consensus Estimate of total revenues of $41 million. IBRX’s total revenues comprise product revenues and a small amount of other revenues. Anktiva unit sales volume is expected to increase 168% year over year for the first quarter of 2026. The company ended the quarter with a solid liquidity position of approximately $380.9 million in cash, cash equivalents, and marketable securities, up from $242.8 million in the fourth quarter of 2025. ImmunityBio is pursuing additional label expansion opportunities for Anktiva. It recently resubmitted a supplemental regulatory filing with the FDA seeking label expansion for the combination of Anktiva and BCG in BCG-unresponsive NMIBC with papillary disease. Within bladder cancer, IBRX is advancing a randomized study evaluating Anktiva plus BCG in BCG-naïve NMIBC patients — a significantly larger population than the currently approved setting. The company is targeting a potential regulatory filing later this year, with additional studies exploring the therapy across other disease settings that could further expand its addressable market. Beyond bladder cancer, ImmunityBio is exploring Anktiva, in combination with standard-of-care therapies and CAR-NK approaches, across several difficult-to-treat cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, glioblastoma, colorectal cancer and hepatocellular carcinoma. In January, the therapy received its first regulatory approval in the NSCLC indication in Saudi Arabia. The company intends to hold discussions with the FDA later this year, seeking label expansion for the drug in a similar indication. IBRX currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals CPRX and Indivior Pharmaceuticals INDV, each currently sporting a Zacks Rank #1 (Strong Buy), and ANI Pharmaceuticals ANIP, which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 9.68% year to date. Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%. Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 9.95% year to date. Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%. Over the past 60 days, estimates for ANI Pharmaceuticals’ 2026 earnings per share have increased from $8.14 to $8.99. Year to date, shares of ANIP have declined 1.52%. ANI Pharmaceuticals' earnings beat estimates in each of the trailing four quarters, with the average surprise being 22.21%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report ImmunityBio, Inc. (IBRX) : Free Stock Analysis Report Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research